Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
The obstetrical research landscape: a cross-sectional analysis of clinical trials from 2007-2020

Jecca R. Steinberg, MD, MSc; Brannon T. Weeks, MD; Griselda A. Reyes, MD; Alison Conway Fitzgerald, MD; Wendy Y. Zhang, BS; Sarah E. Lindsay, MD; Jill N. Anderson, BS; Katelyn Chan, BS; Michael T. Richardson, MD; Christopher J. Magnani, MPhil; Irogue Igbinosa, MD; Anna Girsen, MD; Yasser Y. El-Sayed, MD; Brandon E. Turner, MD, MS; Deirdre J. Lyell, MD

BACKGROUND: Obstetrical complications affect more than a third of women globally, but are underrepresented in clinical research. Little is known about the comprehensive obstetrical clinical trial landscape, how it compares with other fields, or factors associated with the successful completion of obstetrical trials.

OBJECTIVE: This study aimed to characterize obstetrical clinical trials registered on ClinicalTrials.gov with the primary objective of identifying features associated with early discontinuation and results reporting.

STUDY DESIGN: This is a cross-sectional study with descriptive, logistic regression and Cox regression analyses of clinical trials registered on ClinicalTrials.gov. Our primary exposure variables were trial focus (obstetrical or nonobstetrical) and trial funding (industry, United States government, or academic). We conducted additional exploratory analyses of other trial features including design, enrollment, and therapeutic focus. We examined the associations of exposure variables and other trial features with 2 primary outcomes: early discontinuation and results reporting.

RESULTS: We downloaded data for all studies (N=332,417) registered on ClinicalTrials.gov from October 1, 2007, to March 9, 2020, from the Aggregate Analysis of ClinicalTrials.gov database. We excluded studies with a noninterventional design (n=63,697) and those registered before October 1, 2007 (n=45,209). A total of 4276 obstetrical trials (1.9%) (ie, interventional studies) and 219,235 nonobstetric trials (98.1%) were compared. Among all trials, 2.8% of academic-funded trials, 1.9% of United States government-funded trials, and 0.4% of industry-funded trials focused on obstetrics. The quantity of obstetrical trials increased over time (10.8% annual growth rate). Compared with nonobstetrical trials, obstetrical trials had a greater risk of early discontinuation (adjusted hazard ratio, 1.40; 95% confidence interval, 1.21–1.62; P<.0001) and similar odds of results reporting (adjusted odds ratio, 0.89; 95% confidence interval, 0.72–1.10; P=.19). Among obstetrical trials funders after controlling for confounding variables, United States government-funded trials were at the lowest risk of early discontinuation (United States government, adjusted hazard ratio, 0.23; 95% confidence interval, 0.07–0.69; P=.009; industry reference; academic, adjusted hazard ratio, 1.04; 95% confidence interval, 0.62–1.74; P=.88). Academic-funded trials had the lowest odds of results reporting after controlling for confounding variables (academic institutions, adjusted odds ratio, 0.39; 95% confidence interval, 0.22–0.68; P=.0009; industry reference; United States government, adjusted odds ratio, 1.06; 95% confidence interval, 0.53–2.09; P=.87).

CONCLUSION: Obstetrical trials represent only 1.9% of all clinical trials in ClinicalTrials.gov and have comparatively poor completion. All stakeholders should commit to increasing the number of obstetrical trials and improving their completion and dissemination to ensure clinical research reflects the obstetrical burden of disease and advances maternal health.

Key words: ClinicalTrials.gov, industry, maternal-fetal medicine, maternal health, National Institutes of Health, obstetrical complications, obstetrical investigations, obstetrical morbidity, obstetrical studies, research funding

Introduction
Clinical trials represent the gold standard for advancing evidence-based medicine and clinical care. ClinicalTrials.gov is one of the largest international databases of clinical trials, containing nearly half of all registered trials. Since 2007, the United States federal law has required that most phase 2 to 4 intervention studies register in ClinicalTrials.gov.

Obstetrical complications affect nearly a third of women in high-income countries and a greater proportion of women in low-income countries. Despite the perinatal burden of disease, proportionally few clinical trials focus on complications of pregnancy, and pregnant women are often excluded from clinical trials that evaluate therapies used to treat chronic conditions in pregnant women. To address the paucity of obstetrical studies, the National Institutes of Health put forth guidelines to safely include pregnant women in clinical trials and recommended trial breadth capture the spectrum of pharmaceuticals commonly taken during pregnancy. In addition, the World Health Organization, the Institute of Medicine, the Centers for Disease Control and Prevention, and the American College of Obstetricians and Gynecologists called for increased obstetrical clinical trials and for the quantity of obstetrical trials to better match the obstetrical burden of disease.

Despite these initiatives, the landscape and key drivers of obstetrical clinical trial success remain poorly understood. Previous studies describing obstetrical clinical trials examined only small sample sizes or short time frames, and none included multivariable associative
Why was this study conducted?  
This study aimed to characterize obstetrical clinical trials and determine which trial features are associated with trial completion and results reporting.

Key findings  
Less than 2% of clinical trials registered to ClinicalTrials.gov between 2007 and 2020 focused on obstetrics. Obstetrical trials were at a greater risk of early discontinuation than nonobstetrical trials. Among obstetrical trials, United States government–funded trials were least likely to be discontinued early and academic institution–funded trials had the lowest odds of results reporting compared with other funders.

What does this add to what is known?  
This study presents a comparison of obstetrical and nonobstetrical trials that includes funding sources and trial characteristics, novel assessments of temporal trends only possible with a large sample size and greater time period, and a unique examination of associations between obstetrical trial funding and the likelihood of early discontinuation and results reporting, while controlling for confounding variables.

Materials and Methods
Data source
We downloaded data for all studies submitted to ClinicalTrials.gov before March 9, 2020, from the Aggregate Analysis of ClinicalTrials.gov (AACT) database.14 We selected studies after October 1, 2007, to align with the Food and Drug Administration Amendments Act, which mandated the registration of most United States phase 2 to 4 intervention studies in ClinicalTrials.gov.15 After the implementation of the Food and Drug Administration Amendments Act, ClinicalTrials.gov captured a more representative sample of the entire clinical trial landscape, and for many years after, it was the largest database of clinical trials globally.16 We included all registered studies with an intervention study design (i.e., clinical trials). We excluded studies registered before October 1, 2007, and those with an observational design (i.e., not clinical trials). The University Institutional Review Board exempted our study from review because it only involved publicly available data without personal health information or human subjects.

Definitions
Obstetrical and nonobstetrical trials
To identify potential obstetrical trials, we followed a published protocol to identify Medical Subject Heading and disease categories relevant to obstetrical trials.17,18 The protocol for extraction and categorization was set a priori (detailed definitions and labeling methods described in the Appendix). These terms were then used to extract data on all trials relevant to obstetrics from the AACT database.14 Obstetrical trials were manually reviewed, verified, and categorized to one or multiple therapeutic focus categories as follows: cesarean delivery; nutritional status in pregnancy; labor anesthesia and analgesia; infections in pregnancy, labor, and the puerperium; fetal focused; threatened early delivery; mental and behavioral disorder; diabetes mellitus in pregnancy; bleeding and hemorrhage; labor augmentation and induction; hypertensive disorders of pregnancy; breastfeeding; pregnancy loss; obstetrical trauma; thromboembolic disease of pregnancy; vomiting in pregnancy; and other. Nonobstetrical trials were defined as all trials in the AACT database within the same time frame and without content relevant to obstetrics. The 2 first authors and the 7 trained researchers who labeled all trials demonstrated more than 90% agreement on a training set of more than 200 trials. To verify data, the first author randomly selected more than 10% of all labeled trials for concordance with the protocol. The first authors adjudicated all discrepancies in labeling.

For analysis, each therapeutic focus was treated as a binary variable with 2 categories: (1) trials labeled with the therapeutic focus and (2) all other trials that were not labeled with the therapeutic focus.

Exposures and outcomes
Our primary exposure variables were trial focus (obstetrical or nonobstetrical) and trial funding (industry, United States government, or academic). We conducted additional exploratory analyses of other trial features including characteristics, design, enrollment, and therapeutic focus. Obstetrical trials were compared with nonobstetrical trials in terms of funding source and other trial features. Obstetrical trial features were also compared by trial funder.

We examined the associations of the exposure variables and other trial features with 2 primary outcomes: early discontinuation and results reporting within 3 years of trial completion. “Early discontinuation” was defined as a trial stopped early with the status “Terminated” or “Suspended.” In analysis of early discontinuation, we excluded trials documented as having a duration of <1 day (2.1%), trials with the status “Withdrawn” (defined as those terminating before the enrollment of participants [2.8%]), and trials without a verified status (13.2%). Only trials completed by March 9, 2017, were included in the analysis of results reporting to align with federal mandates for delayed submission of results within 3 years of trial completion.20

analyses.5,11—13 A comprehensive understanding of obstetrical clinical trials to date presents a first step toward determining how to improve and expand the evidence base. In view of the importance of clinical trials informing evidence-based care, we sought to characterize and analyze key features of obstetrical studies registered on ClinicalTrials.gov and to identify factors associated with early trial discontinuation and results reporting.
Trial features
We categorized 12 trial features for comparison and exposure analysis: (1) funding, (2) primary purpose, (3) phase, (4) number of arms, (5) enrollment, (6) year of trial registration, (7) blinding, (8) randomization, (9) oversight by a data safety monitoring committee, (10) location, (11) number of sites, and (12) study status.17

“Enrollment” included both actual enrollment (for completed trials) and anticipated enrollment (for ongoing trials with continued enrollment).

We classified “funding” consistently with previous studies based on the trial sponsor and collaborating agencies.17,18 If industry was a trial’s sponsor or a collaborator, the trial was classified as “industry.” Among remaining trials, if the United States government (ie, National Institutes of Health or another United States government agency) was the sponsor or a collaborator, the trial was classified as “United States government.” The remaining trials were categorized “academic” after a random sample analysis of 2500 remaining funders identified that 90.1% (99% confidence interval [CI], 88.56–91.64) of these funding sources were academic institutions as defined with United States legal code.21,22

“Location” was classified based on the World Bank definitions of high-, middle-, and low-income countries.23 Trials with at least 1 site in a high-income country were considered high income, and those in low- and middle-income countries were considered low and middle income.

Analysis
We summarized data with descriptive statistics including frequencies, percentages, and 2-sided Pearson chi-square tests. We analyzed change over time— independence and significance with annual growth rates and post hoc Mann-Kendall tests, respectively.24 Only years with a completed 12-month cycle were included in growth analyses (2008–2019).

We conducted univariable and multivariable analyses with Cox proportional hazard models for early discontinuation and logistic regression for results reporting resulting in adjusted hazard ratios (aHRs) and adjusted odds ratios (aORs). Although we created Kaplan-Meier curves for both outcomes, the analysis of results reporting used only a logistic model. Cox models for early discontinuation use a time variable consistent with the duration of each trial from initiation to either discontinuation (event) or if ongoing the data download date. Log-rank tests were used to verify the independence of the Kaplan-Meier curves. All 12 trial features listed earlier, except for the trial feature under investigation, were treated as confounding variables in multivariable analysis.

All analyses were 2 sided with statistical significance at the α=.05 level. Analyses were performed using the R statistical programming language, version 3.5.0 (The R Foundation, https://www.r-project.org/).

Missing data
Multiple imputation analysis and multiple imputation by chained equations were conducted for all missing data in multivariable analysis.25,26 We generated 20 imputed datasets and modeled continuous data using Bayesian linear regression, binary data with Bayesian logistic regression, and categorical data with Bayesian polytomous regression, all with analytical variables as covariables. Parameters of interest were estimated separately in each imputed dataset and subsequently pooled using Rubin’s rules.27 We present the imputed outcomes in results.

FIGURE 1
CONSORT diagram of clinical trials included in the analysis

332,417 studies that were registered before March 1, 2020

108,906 Studies Excluded

63,697 observational studies that were not clinical trials

45,209 clinical trials registered before October 1, 2007

223,511 clinical trials with an interventional study design registered after October 1, 2007

4,276 clinical trials with relevance to the field of obstetrics

219,235 clinical trials without relevance to the field of obstetrics

CONSORT, Consolidated Standards of Reporting Trials.
Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
Results

Trial population

A total of 332,417 studies were registered in ClinicalTrials.gov on March 9, 2020; 108,906 studies were excluded because they were registered before 2007 (n=45,209) or had a noninterventional study design (n=63,697) (Figure 1). Of the trials included, 1.9% (n=4276) were obstetrical trials, with more than 3.4 million estimated participants, and 98.1% (n=219,235) were nonobstetrical comparison trials.

Obstetrical trials compared with nonobstetrical trials

Funding

The funding sources of obstetrical trials differed from nonobstetrical trials, with the vast majority of obstetrical clinical trials funded by academic institutions (85.5%) followed by the United States government (7.7%) and industry (6.8%) (Figure 2; Supplemental Table 1). In contrast, a large proportion of nonobstetrical trials were funded by both academic institutions (57.1%) and industry (35.0%), with a smaller proportion funded by the United States government (7.9%). Among all trials, obstetrics was the focus in 2.8% of academic-funded trials, 1.9% of United States government–funded trials, and 0.4% of industry-funded trials.

Other trial characteristics

Obstetrical trials focused on prevention more frequently (31.5% vs 10.2%) and on treatment less frequently than nonobstetrical trials (39.3% vs 64.0%) (Supplemental Table 1). Obstetrical trials had more participants per trial (enrollment of >100, 61.5% vs 35.4%) and had more frequent blinding, randomization, and reporting to a data safety monitoring committee. A greater proportion of obstetrical trials occurred exclusively in low- and middle-income countries (27.5%) than nonobstetrical trials (13.9%). The quantity of obstetrical trials increased at a greater annual growth rate than nonobstetrical trials (obstetrical 10.8% vs nonobstetrical 4.8%) (Supplemental Table 2).

Obstetrical trial characteristics

Funding

Within obstetrical trials, compared with other sources of funding, those with United States government funding had more randomization, increased enrollment (>100), and more oversight by a data safety monitoring committee (Table 1). In contrast, a greater proportion of obstetrical trials with industry funding...
TABLE 1
Characteristics of obstetrical trials by funding\textsuperscript{a,b}

| Trial feature               | Industry | Academic | United States government | Chi\textsuperscript{2} $P$-value |
|-----------------------------|----------|----------|--------------------------|---------------------------------|
| Total                       | 290 (6.8)| 3655 (85.6)| 331 (7.7)                |                                 |
| Primary purpose             |          |          |                          |                                 |
| Treatment                   | 116 (40.0)| 1467 (40.1)| 98 (29.6)                | .0002                           |
| Basic science               | 5 (1.7)  | 84 (2.3)  | 17 (5.1)                 |                                 |
| Prevention                  | 92 (31.7)| 1119 (30.6)| 134 (40.5)               |                                 |
| Other\textsuperscript{c}    | 67 (23.1)| 894 (24.5)| 76 (23.0)                |                                 |
| Missing                     | 10 (3.4) | 91 (2.5)  | 6 (1.8)                  |                                 |
| Phase                       |          |          |                          |                                 |
| Not Applicable\textsuperscript{d} | 127 (43.8)| 2455 (67.2)| 223 (67.4)               | <.0001                          |
| Phase 1                     | 13 (4.5) | 107 (2.9) | 16 (4.8)                 |                                 |
| Phase 1/2—2                 | 46 (15.9)| 221 (6.0) | 34 (10.3)                |                                 |
| Phase 2/3—3                 | 58 (20.0)| 414 (11.3)| 35 (10.6)                |                                 |
| Phase 4                     | 46 (15.9)| 458 (12.5)| 23 (6.9)                 |                                 |
| Enrollment\textsuperscript{e} |          |          |                          |                                 |
| 0—9                         | 25 (8.6) | 169 (4.6) | 10 (3.0)                 | <.0001                          |
| 10—49                       | 57 (19.7)| 545 (14.9)| 39 (11.8)                |                                 |
| 50—99                       | 38 (13.1)| 688 (19.1)| 53 (16.0)                |                                 |
| 100—499                     | 115 (39.7)| 1655 (45.3)| 140 (42.3)               |                                 |
| 500—999                     | 24 (8.3) | 237 (6.5) | 34 (10.3)                |                                 |
| >999                        | 30 (10.3)| 337 (9.2) | 55 (16.6)                |                                 |
| Missing                     | 1 (0.3)  | 14 (0.4)  | 0                        |                                 |
| Blinding                    |          |          |                          |                                 |
| None                        | 166 (57.2)| 1926 (52.7)| 174 (52.6)               | <.0001                          |
| Single                      | 31 (10.7)| 947 (25.9)| 100 (30.2)               |                                 |
| Double                      | 93 (32.1)| 773 (21.1)| 56 (16.9)                |                                 |
| Missing                     | 0        | 9 (0.2)   | 1 (0.3)                  |                                 |
| Randomization               |          |          |                          |                                 |
| Nonrandomized               | 80 (27.6)| 706 (19.3)| 36 (10.9)                | <.0001                          |
| Randomized                  | 207 (71.4)| 2918 (79.8)| 295 (89.1)               |                                 |
| Missing                     | 3 (1.0)  | 31 (0.8)  | 0                        |                                 |
| Oversight by a data safety monitoring committee |          |          |                          |                                 |
| No                          | 155 (53.4)| 1976 (54.1)| 138 (41.7)               | <.0001                          |
| Yes                         | 120 (41.4)| 1341 (36.7)| 174 (52.6)               |                                 |
| Missing                     | 15 (5.2) | 338 (9.2) | 19 (5.7)                 |                                 |
| Location                    |          |          |                          |                                 |
| High-income countries       | 210 (72.4)| 2125 (58.1)| 222 (67.1)               | <.0001                          |
| Low- and middle-income countries only | 47 (16.2)| 1048 (28.7)| 79 (23.9)                |                                 |
| Missing                     | 33 (11.4)| 482 (13.2)| 30 (9.1)                 |                                 |
| Therapeutic focus\textsuperscript{f} |          |          |                          |                                 |
| Infection                   | 55 (19.0)| 283 (7.7) | 100 (30.2)               | <.0001                          |

\textsuperscript{a} Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
had lower enrollment (<100), no blinding, and no randomization.

**Change over time**
The total number of obstetrical trials doubled from 2007 to 2013 (n=1366) to 2014 to 2020 (n=2910) (Figure 2). The increase in obstetrical trials varied by funding source: academic-funded trials increased at nearly double the rate of industry-funded trials, and United States government-funded trials had no meaningful change (Supplemental Table 2).

**Therapeutic focus**
The plurality of obstetrical trials focused on cesarean delivery (16.0% of all obstetrical trials) (Supplemental Table 3) with most of these funded by academic institutions (Table 1). Infection was the most frequent therapeutic focus among both industry- (19.0%) and United States government–funded trials (30.2%). Obstetrical trauma, thrombosis, and vomiting were the least frequent therapeutic foci across all funders with the lowest enrollment (Supplemental Figure; Supplemental Table 3).

**Early trial discontinuation**
**Obstetrical trials compared with nonobstetrical trials**
Between 2007 and 2020, 47.5% of all obstetrical trials reached completion, representing more than 2.8 million participants (Supplemental Table 4). A total of 7.2% trials were discontinued early and 13.2% had missing or unknown study status. Compared with nonobstetrical trials, obstetrical trials had a greater adjusted risk of early discontinuation (aHR, 1.40; 95% CI, 1.21–1.62; P<.0001) (Table 2; unadjusted analysis results in Supplemental Table 5).

**Obstetrical trials only**
Among obstetrical trials, United States government–funded trials had the lowest adjusted risk of early discontinuation of any funding source (United States government, aHR, 0.23; 95% CI, 0.07–0.69; P=.009, industry reference; academic, aHR, 1.04; 95% CI, 0.62–1.74; P=.88, Figure 3). Randomized trials and trials in high-income countries had a greater adjusted hazard of early discontinuation than nonrandomized trials and trials exclusively in low- and middle-income countries, respectively (randomization, aHR, 2.00; 95% CI, 1.28–3.13; P=.002; location, aHR, 1.83; 95% CI, 1.05–3.21; P=.03). Trials with the therapeutic foci of either anesthesia or cesarean delivery showed a greater adjusted hazard of early discontinuation.

### Table 1

| Trial feature          | Industry | Academic | United States government | Chi² P value |
|------------------------|----------|----------|--------------------------|--------------|
| Nutrition              | 40 (13.8)| 458 (12.5)| 55 (16.6)                | .10          |
| Fetal                  | 27 (9.3 )| 378 (10.3)| 17 (5.1)                 | .009         |
| Early delivery         | 25 (8.6 )| 292 (8.0 )| 11 (3.3)                 | .002         |
| Diabetes mellitus      | 22 (7.6 )| 266 (7.3 )| 19 (5.7)                 | .56          |
| Mental health          | 21 (7.2 )| 267 (7.3 )| 66 (19.9)                | <.0001       |
| Cesarean delivery      | 19 (6.6 )| 659 (18.0)| 8 (2.4)                  | <.0001       |
| Labor Augmentation     | 19 (6.6 )| 235 (6.4 )| 3 (0.9)                  | .0002        |
| Hemorrhage             | 19 (6.6 )| 281 (7.7 )| 5 (1.5)                  | .0001        |
| Hypertension           | 13 (4.5 )| 229 (6.3 )| 12 (3.6)                 | .08          |
| Breastfeeding          | 10 (3.4 )| 158 (4.3 )| 29 (8.8)                 | .0006        |
| Anesthesia             | 10 (3.4 )| 501 (13.7)| 4 (1.2)                  | <.0001       |
| Trauma                 | 7 (2.4 ) | 85 (2.3 ) | 3 (0.9)                  | .24          |
| Pregnancy loss         | 6 (2.1 ) | 139 (3.8 )| 4 (1.2)                  | .02          |
| Thromboembolic         | 3 (1.0 ) | 21 (0.6 ) | 0                        | .22          |
| Vomiting               | 2 (0.7 ) | 17 (0.5 ) | 2 (0.6)                  | .83          |
| Other                  | 37 (12.8)| 441 (12.1)| 44 (13.3)                | .77          |

Values are number (percentage) unless indicated otherwise.

- Percentages may not sum up to 100 because of rounding.
- Funding categories were determined with data on the sponsor and collaborators. Industry funding includes trials with an industry sponsor or collaborating agency. United States government trials include remaining trials with a United States government sponsor or collaborating agency. Academic trials include all other trials.
- Other primary purposes include diagnostic, screening, supportive care, health services research, and other.
- On ClinicalTrials.gov, “Not Applicable” is used to describe trials without Food and Drug Administration–defined phases, including trials of devices or behavioral interventions.
- Enrollment included both actual enrollment (for completed trials) and anticipated enrollment (for ongoing trials with planned enrollment).
- Trials could have >1 therapeutic focus. For analysis, each therapeutic focus was treated as a binary variable.

Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
| Trial feature                                                                 | Hazard ratio (95% confidence interval) | P value |
|-----------------------------------------------------------------------------|----------------------------------------|---------|
| All trials                                                                  |                                        |         |
| Nonobstetrical                                                              | Reference                               |         |
| Obstetrical                                                                 | 1.40 (1.21—1.62)                       | <.0001  |
| Obstetrical trials only                                                     |                                        |         |
| Funding<sup>a</sup>                                                          |                                        |         |
| Industry                                                                     | Reference                               |         |
| Academic                                                                     | 1.04 (0.62—1.74)                       | .88     |
| United States government                                                     | 0.23 (0.07—0.69)                       | .009    |
| Primary purpose                                                              |                                        |         |
| Treatment                                                                    | Reference                               |         |
| Basic science                                                                | 0.58 (0.17—1.99)                       | .38     |
| Prevention                                                                   | 0.95 (0.64—1.42)                       | .82     |
| Other<sup>b</sup>                                                            | 1.33 (0.87—2.03)                       | .19     |
| Phase                                                                        |                                        |         |
| Phase 2/3—3                                                                 | Reference                               |         |
| Not Applicable<sup>c</sup>                                                  | 0.54 (0.34—0.86)                       | .009    |
| Phase 1                                                                      | 0.52 (0.25—1.09)                       | .08     |
| Phase 1/2—2                                                                 | 0.64 (0.33—1.23)                       | .18     |
| Phase 4                                                                      | 1.17 (0.67—2.04)                       | .15     |
| Enrollment<sup>d</sup>                                                       |                                        |         |
| 100—499                                                                     | Reference                               |         |
| 0—9                                                                         | 49.82 (30.10—82.47)                    | <.0001  |
| 10—49                                                                       | 6.29 (4.10—9.64)                       | <.0001  |
| 50—99                                                                       | 2.01 (1.20—3.36)                       | .007    |
| 500—999                                                                     | 0.72 (0.25—2.02)                       | .53     |
| >999                                                                        | 0.79 (0.37—1.65)                       | .53     |
| Blinding                                                                     |                                        |         |
| None                                                                        | Reference                               |         |
| Single                                                                      | 0.62 (0.40—0.96)                       | .03     |
| Double                                                                      | 0.83 (0.54—1.26)                       | .37     |
| Randomization                                                                |                                        |         |
| Nonrandomized                                                                | Reference                               |         |
| Randomized                                                                   | 2.00 (1.28—3.13)                       | .002    |
| Oversight by a data safety monitoring committee                              |                                        |         |
| No                                                                           | Reference                               |         |
| Yes                                                                          | 1.12 (0.82—1.54)                       | .47     |
| Location                                                                     |                                        |         |
| Low- and middle-income country only                                          | Reference                               |         |
| High-income country                                                          | 1.83 (1.05—3.21)                       | .03     |

*Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.*
discontinuation than any other therapeutic foci.

**Results reporting**

**Obstetrical trials compared with nonobstetrical trials**

Obstetrical trials had similar adjusted odds of reporting results as nonobstetrical trials (aOR, 0.89; 95% CI, 0.72–1.10; P=.19) (unadjusted analysis results in Supplemental Table 6, adjusted analysis results in Supplemental Table 7).

**Obstetrical trials only**

By March 8, 2017, a total of 1411 obstetrical trials (102 industry, 138 United States government, and 1171 academic) had reached completion, but only 216 (15.3%) reported results to ClinicalTrials.gov by March 9, 2020 (Supplemental Tables 6 and 8).

Among obstetrical trials, academic-funded trials had the lowest adjusted odds of reporting results compared with other funders (academic, aOR, 0.39; 95% CI, 0.22–0.68; P=.0009; industry reference; United States government, aOR, 1.06; 95% CI, 0.53–2.09; P=.87) (Figure 4; Supplemental Table 5). Trials that focused on cesarean deliveries had the greatest adjusted odds of reporting results (aOR, 2.07; 95% CI, 1.29–3.34; P=.003) compared with other trial foci. Trials in high-income counties had greater results reporting than those exclusively in low- and middle-income countries (aOR, 2.13; 95% CI, 1.35–3.36; P=.001).

**Comment**

**Principal findings**

This study demonstrates that obstetrical clinical trials represent <2% of all clinical trials and, when initiated, are at a greater risk of early discontinuation than nonobstetrical trials. Although obstetrical trials report results at a similar rate to nonobstetrical, only 15.3% of completed obstetrical trials report results. Our temporal analysis shows limited improvement in obstetrical trial quantity, almost entirely driven by academic institutions.

Our study adds to previous investigations of obstetrical trials by suggesting the link among funding, metrics of trial quality, trial completion, and results reporting. We found that, among obstetrical trials, industry funds proportionally fewer large-scale trials, blinded trials, and randomized trials. In contrast, United States government–funded obstetrical trials are the most likely to meet the Consolidated Standards of Reporting Trials recommendations for trial quality and to reach completion. When examining results reporting by funder, even after controlling for other variables, we identified that academic-funded trials are least likely to report results compared with other funders.

**Results in context**

Notably, 4 previous investigations have analyzed obstetrical trials in the ClinicalTrials.gov registry, all using a smaller sample of trials (n=325 trials and n=5 trials) or covering a shorter time span (2013–2014 and 2007–2012). Although previous studies suggest that obstetrics is the focus of 6% of all trials and 1% to 16% of industry-funded trials in ClinicalTrials.gov, our findings paint a bleaker picture; we found that only 1.9% of trials and 0.4% of industry-funded trials focus
on obstetrics. Even with the inclusion of observational studies, the 6% estimate in Stockmann et al’s investigation still likely overrepresents obstetrical clinical trials, perhaps because their search query included neonatal terms and the study did not describe a manual review to remove trials unrelated to obstetrics after the query. Moreover, 3 of the previous obstetrical studies were limited to Federal and Drug Administration–approved trials, pharmaceutical trials, and phase 4 trials, respectively. We included all obstetrical clinical trials

FIGURE 3
Kaplan-Meier curves of early discontinuation by trial funder

Funding categories were determined with data on the sponsor and collaborators. Industry funding includes trials with an industry sponsor or collaborating agency. United States government trials include remaining trials with a United States government sponsor or collaborating agency. Academic trials include all other trials. The log-rank $P$ value for Kaplan-Meier curve was <.0001.

Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
between 2007 and 2020, but similarly found the number of obstetrical studies pales in comparison with that of other fields.

More studies were dedicated to oncology (8992), cardiology (3437), and mental health between 2007 and 2010 (3695) than those dedicated to obstetrics in the decade after 2007 (3166). The paucity of obstetrical studies carries implications in the changing international health ecosystem. One recent

Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
study found that only 1.7% of coronavirus disease 2019 research pertains to pregnancy.\(^\text{30}\) Our findings suggest the limited number of obstetrical trials may correlate to the dearth of industry funding in obstetrics. Previous investigations have indicated that industry may forgo obstetrical trials owing to inadequate pipelines for obstetrical drug and device development,\(^\text{31}\) regulatory and financial prioritization of participant homogeneity,\(^\text{32}\) and avoidance of potential maternal and fetal liability.\(^\text{33}\) This is an important delineation, because industry is one of the most significant contributors to production, marketing, and distribution of new therapies.\(^\text{34}\) Furthermore, this deficit may have untoward implications for the development of pharmaceuticals and treatments specific for obstetrical conditions.

**Clinical implications**

Despite calls by leading experts and international organizations to increase obstetrical clinical trials,\(^\text{10,35}\) the relative shortage in obstetrical clinical trials remains an urgent issue. Other studies have explored the multifaceted etiology of obstetrical trial scarcity including historical precedents, ethical quandaries, participant, funder and institutional review board reluctance, and risk assessment.\(^\text{10,36,37}\) A recent report recommended increased funding from the National Institutes of Health specifically as a means to expand obstetrical and gynecologic research and improve women’s health outcomes.\(^\text{38}\) Obstetrical clinical research represents a key component of the multifaceted efforts needed to decrease the maternal burden of disease and advance treatments for obstetrical conditions.\(^\text{4,35}\) The progress of the field warrants and partially depends on a greater commitment of resources and funding by all clinical trial sponsors.

In addition to increasing the number of obstetrical clinical trials, improvement in obstetrical trial completion and dissemination is important. We found that United States government—funded trials more consistently meet quality metrics (e.g., sample size, randomization, blinding, and oversight by a data safety monitoring committee)\(^\text{28}\) and more frequently reach completion than academic or industry trials. The quality and success of United States government—funded obstetrical trials may speak to the potential role of increased regulation and present a model for increasing obstetrical trials completion.

The low results reporting, particularly in academic-funded trials, may be a reflection of relatively limited resources in academia. Although federal statutes require many clinical trials to report their results within one year with the option to delay for 2 years,\(^\text{20}\) the parameters of the statutes have evolved over the past decade and barriers exist to consistent results reporting.\(^\text{15,39–41}\) Stockmann et al.\(^\text{12}\) identified that for obstetrical trials, ClinicalTrials.gov provides the most complete repository for trial results, which is more comprehensive than peer-reviewed publications. Trial results and their implications take on a greater nuance in pregnancy trials where interventions may affect both maternal and fetal health.\(^\text{12}\) A lack of results can bias the literature, squander limited resources, and hinder medical innovation. Greater results reporting within obstetrical trials continues to be a relevant goal with implications for all expecting parents.

**Strengths and limitations**

Our analysis uniquely compares obstetrical and nonobstetrical trials and trial features among different funders. This comparison allows for the extrapolation of factors that may contribute to the low number of obstetrical trials and the increased risk of early discontinuation among obstetrical trials. We present novel assessments of temporal trends only possible with a large sample size and greater time period. This study examines the associations between obstetrical trial funding and early discontinuation and results reporting while controlling for confounding variables. Our multivariable approach clarifies which trial features are most important when considering mechanisms to improve obstetrical clinical trial completion and dissemination.

Our study is not without limitations. First, the ClinicalTrials.gov registry represents only a sample of all global clinical trials.\(^\text{15}\) However, 1 study found that ClinicalTrials.gov contains the greatest number of obstetrical trials compared with other databases.\(^\text{11}\) Second, because this analysis involves multiple testing, it is possible that the strength of association seen for some trial features may be the result of chance. Finally, the limitations of ClinicalTrials.gov have been described in other studies and apply to this analysis. These include changes to the database over time,\(^\text{40}\) nuances of recruitment description and progress,\(^\text{12}\) the inability to verify the validity of all trial data,\(^\text{18}\) and the limited trial features and descriptions available for analysis.

**Research implications**

We characterize the obstetrical clinical trial landscape and trial features associated with early discontinuation and results reporting. A more granular view of the research by disease category and analyses comparing trial quantity with burden of disease could highlight areas for increased clinical trial focus. In addition, manual reviews of trial discontinuation reasons could identify why trials in obstetrics discontinue early.

**Conclusions**

The obstetrical clinical trial portfolio remains sparse but has shown growth over time. Increased industry investment in obstetrical trials may present an important step toward expanding available obstetrical therapies. All stakeholders must commit to improving obstetrical clinical trial completion rates and results dissemination to ensure trial findings advance the maternal health evidence base. Clinical trial research—in conjunction with health system strengthening and effective national policies—could decrease maternal morbidity and mortality.\(^\text{11}\) Improvement in obstetrical outcomes depends, in part, on research investments that bridge the gap between the breadth of obstetrical disease and the quantity, quality, and...
dissemination of obstetrical clinical trials.

References

1. Zarin DA, Tse T, Williams RJ, Califf RM, Ide NC. The ClinicalTrials.gov results database—update and key issues. N Engl J Med 2011;364:852–60.
2. Banno M, Tsujimoto Y, Kataoka Y. Studies registered in non-ClinicalTrials.gov accounted for an increasing proportion of protocol registrations in medical research. J Clin Epidemiol 2019;116:106–13.
3. Tse T, Williams RJ, Zarin DA. Reporting “basic results” in ClinicalTrials.gov. Chest 2009;136:295–303.
4. Kassebaum NJ, Bertozzi-Villa A, Coggeshall MS, et al. Global, regional, and national levels and causes of maternal mortality during 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2014;384:980–1004.
5. Shields KE, Lyerly AD. Exclusion of pregnant women from industry-sponsored clinical trials. Obstet Gynecol 2013;122:1077–81.
6. Sheffield JS, Siegel D, Mirochnick M, et al. Designing drug trials: considerations for pregnant women. Clin Infect Dis 2014;59(Suppl 7):S437–44.
7. Vallotton MB. Council for international organizations of medical sciences perspectives: protecting persons through international ethics guidelines. Int J Integr Care 2010;10(Suppl e008).
8. Thomson A. Women and health research, ethical and legal issues of including women in clinical studies. Midwifery 1995;11:52.
9. Broussard CS, Frey MT, Hernandez-Diaz S, et al. Developing a systematic approach to safer medication use during pregnancy: summary of a Centers for Disease Control and Prevention–convened meeting. Am J Obstet Gynecol 2014;211:208–14.e1.
10. Committee on Ethics, American College of Obstetricians and Gynecologists. ACOG Committee Opinion no. 377: Research involving women. Obstet Gynecol 2007;110:731–8.
11. Scaffidi J, Mol BW, Keelan JA. The pregnant women as a drug orphan: a global survey of registered clinical trials of pharmacological interventions in pregnancy. BJOG 2017;124:132–40.
12. Stockmann C, Sherwin CMT, Koren G, et al. Characteristics and publication patterns of obstetric studies registered in Clin Trials.gov. J Clin Pharmacol 2014;54:432–7.
13. Checketts JX, Evans MB, Athale AH, et al. Compliance on mandatory data reporting in registered obstetrics trials. Am J Perinatol 2018;35:1192–6.
14. NMC. Clinical trials transformation initiative. 2018. Available at: https://www.ctti-clinicaltrials.org/. Accessed January 2, 2019.
15. Tse T, Fan K, Zarin DA. How to avoid common problems when using ClinicalTrials.gov in research: 10 issues to consider. BMJ 2018;361:k1452.
16. Wiergerve RF, Gherzi D. The quality of registration of clinical trials. PLoS One 2011;6:e14701.
17. Turner B, Rajeshuni N, Tran EM, et al. Characteristics of ophthalmology trials registered in ClinicalTrials.gov, 2007-2018. Am J Ophthalmol 2020;211:132–41.
18. Liu X, Zhang Y, Tang LL, et al. Characteristics of radiotherapy trials compared with other oncological clinical trials in the past 10 years. JAMA Oncol 2018;4:1073–9.
19. ClinicalTrials.gov. protocol registration data element definitions for interventionaland observational studies. ClinicalTrials.gov. Available at: https://prsinfo.clinicaltrials.gov/definitions.html. Accessed October 23, 2019.
20. FDAAA 801 and the final rule. ClinicalTrials.gov. Available at: https://clinicaltrials.gov/ct2/manage-recs/Idaaa#WhenDidI需ToSubmitResults. Accessed May 28, 2020.
21. Discrimination based on sex or blindness, 20 USC ch 38, §1681 (2020). Available at: https://uscode.house.gov/view.xhtml?req=granuleid:USC-prelim-title20-section1681&num=0edition =prelim. Accessed October 30, 2019.
22. General definition of institution of higher education, 20 USC ch 28, §1001 (2012). Available at: https://www.law.cornell.edu/uscode/text/20/1001. Accessed October 30, 2019.
23. Countries and economies. The World Bank Group. 2020. Available at: https://data.worldbank.org/country. Accessed March 23, 2020.
24. McLeod Al. Kendall rank correlation and Mann-Kendall trend test. 2012. Available at: http://br0r2x.zt.uni-bayreuth.de/math/statlib/R/CRAN/doc/packages/Kendall.pdf. Accessed September 27, 2019.
25. Campion WM. Multiple imputation for nonresponse in surveys by Donald B. Rubin. J Mark Res 1989;26:485–6.
26. Moher D, Schulz KF, Altman DG; CONSORT. The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials. BMC Med Res Methodol 2001;11:12.
27. Califf RM, Zarin DA, Kramer JM, Sherman RE, Aberle LH, Tasneem A. Characteristics of clinical trials registered in ClinicalTrials.gov, 2007-2010. JAMA 2012;307:1838–47.
28. Smith DD, Pippen JL, Adesomo AA, Rood KM, Landon MB, Costantine MM. Exclusion of pregnant women from clinical trials during the coronavirus disease 2019 pandemic: a review of international registries. Am J Perinatol 2020;37:792–9.
29. Fisk NM, Atun R. Market failure and the poverty of new drugs in maternal health. PLoS Med 2008;5:e22.
30. Nazha B, Mishra M, Pentz R, Owonikoko TK. Enrollment of racial minorities in clinical trials: old problem assumes new urgency in the age of immunotherapy. Am Soc Clin Oncol Educ Book 2019;39:3–10.
31. van der Graaf R, van der Zande ISE, den Ruijter HM, et al. Fair inclusion of pregnant women in clinical trials: an integrated scientific and ethical approach. Trials 2018;19:78.
32. Moses H 3rd, Matheson DH, Cairns-Smith S, George BP, Palsich C, Dorsey ER. The anatomy of medical research: US and international comparisons. JAMA 2015;313:174–89.
33. D’Alton ME, Friedman AM, Bernstein PS, et al. Putting the “M” back in maternal-fetal medicine: a 5-year report card on a collaborative effort to address maternal morbidity and mortality in the United States. Am J Obstet Gynecol 2019;221:311–7.e1.
34. Baylis F. Pregnant women deserve better. Nature 2010;465:689–90.
35. Palmer S, Budwell J, Smith GN, Reid RL. Optimizing participation of pregnant women in clinical trials: factors influencing decisions about participation in medication and vaccine trials. J Obset Gynaecol Can 2016;38:945–54.
36. Rice LW, Cedars MI, Sabovsky Y, et al. Increasing NIH funding for academic departmetns of obstetrics and gynecology: a call to action. Am J Obstet Gynecol 2020;223:79.e1–5.
37. Zarin DA, Tse T, Williams RJ, Carr S. Trial reporting in ClinicalTrials.gov, 2007-2010. Am J Med 2015;2014:35:1361–2.
38. Turner B, Rajeshuni N, Tran EM, et al. Characteristics of ophthalmology trials registered in ClinicalTrials.gov, 2007-2018. Am J Ophthalmol 2020;211:132–41.
39. Alton ME, Friedman AM, Bernstein PS, et al. Putting the “M” back in maternal-fetal medicine: a 5-year report card on a collaborative effort to address maternal morbidity and mortality in the United States. Am J Obstet Gynecol 2019;221:311–7.e1.
40. Anderson ML, Chiswell K, Peterson ED, Tasneem A, Topping J, Califf RM. Compliance with results reporting at ClinicalTrials.gov. N Engl J Med 2015;372:1031–9.
41. DeVito NJ, Bacon S, Goldacre B. Compliance with legal requirement to report clinical trial results on ClinicalTrials.gov: a cohort study. Lancet 2020;395:361–9.
42. Jean S, Hurtado K. FDA Regulations and Definitions, FDA & HHS Similarities and Differences, Applicability of Each. Available at: https://oprs.usc.edu/files/2017/05/Wk3.pdf. Accessed September 24, 2018.

Author and article information

From the Department of Obstetrics and Gynecology, Northwestern University Feinberg School of Medicine, Chicago, IL (Dr Steinberg); Department of Obstetrics and Gynecology, Stanford Medical School, Stanford, CA (Drs Weeks, Fitzgerald, and Lindsay; Miss Anderson and Chan; Mr Magnani, and Drs Igbinosa, Girsen, El-Sayed, Turner, and Lytell); Department of Obstetrics & Gynecology, University of California, Irvine, Orange, CA (Dr Reyes and Ms Zhang); and Department of Obstetrics and Gynecology, University of California, Los Angeles, Los Angeles, CA (Dr Richardson).

Received Sept. 24, 2020; accepted Sept. 26, 2020. The authors report no conflict of interest.

Drs Steinberg and Weeks are co-first authors. Drs Lytell and Turner are co-senior authors.

This study was presented at the Society for Maternal-Fetal Medicine February 3-8, 2020, Grapevine, Texas. Corresponding author: Jecca R. Steinberg, MD, MSc. jeccasteinberg@gmail.com
Appendix

Obstetrical therapeutic focus and disease category definitions and subgroups

A total of 8 researchers were trained with respect to the obstetrical therapeutic focus categorization system. Collectively, they manually reviewed all trials including titles, abstracts, and detailed descriptions to verify and categorize obstetrical trials. Disagreements and inconsistencies were adjudicated by the lead authors (J.R.S. and B.T.W.).

For analysis, each therapeutic focus was treated as a binary variable with 2 categories: (1) trials labeled with the therapeutic focus and (2) all other trials that were not labeled with the therapeutic focus (eg, [1] trials with the label “pregnancy loss,” [2] trials without the label “pregnancy loss”). The reference for multivariate analysis of associations of therapeutic foci with trial outcomes was (2) all other trials that were not labeled with the therapeutic focus. Trials in the reference subsequently varied among therapeutic foci.

The labels listed below were used to categorize the therapeutic foci of different obstetrical trials:

1. Cesarean delivery: All trials focused on cesarean delivery interventions or conducted only in patients receiving cesarean deliveries
2. Nutritional status in pregnancy: Trials that focused on obesity, malnutrition, mineral deficiencies, and/or amino acid deficiencies
3. Labor anesthesia and analgesia: Trials that focused on complications of anesthesia during pregnancy or after delivery, including pulmonary, cardiac, and central nervous system complications; toxic reaction to local anesthesia; spinal and epidural anesthesia-induced complications, including headache; and/or failed or difficult intubation
4. Infections in pregnancy, labor, and the puerperium: Trials that focused on chorioamnionitis; infections of genital and urinary tracts; sexually transmitted infections and pregnancy; viral hepatitis, HIV, and other viral infection; protozoal diseases; breast infections; pneumonia; tuberculosis; infection of the obstetrical surgical wound; fever of unknown origin; and/or sepsis
5. Fetal focused: Trials that focused on prenatal genetic screening, preimplantation genetic diagnosis, nonstress testing, intrapartum fetal heart rate monitoring, fetal (not neonatal) abnormalities, multiple gestation, polyhydramnios, oligohydramnios, hydrops, macrosomia, intrauterine growth restriction, and/or malpresentation
6. Threatened early delivery: Trials that focused on preterm labor, false labor, cervical insufficiency, and/or premature rupture of membranes
7. Mental and behavioral disorders: Trials that focused on postpartum mood disturbance or blues and/or postpartum depression or psychosis
8. Diabetes mellitus in pregnancy: Trials that focused on preexisting diabetes mellitus complicating pregnancy; and/or gestational diabetes
9. Bleeding and hemorrhage: Trials that focused on hemorrhage and spotting in early pregnancy; antepartum, intrapartum, and postpartum hemorrhage; placenta previa; placental abruption; placenta accreta, increta, and percreta; and/or postpartum uterine atony
10. Labor augmentation and induction: Trials that focused on postdates pregnancy, cervical ripening, induction of labor, and/or prolonged labor
11. Hypertensive disorders of pregnancy: Trials that focused on preexisting hypertension complicating the pregnancy, edema and proteinuria, pregnancy-induced hypertension, and/or preeclampsia and eclampsia
12. Breastfeeding: Trials that focused on breastfeeding, nipple pain-trauma, nipple infection, duct pathology, mastitis, breast abscess, and galactocele and hypogalactica
13. Pregnancy loss: Trials that focused on early pregnancy loss, ectopic pregnancy, spontaneous abortion, and/or fetal reduction
14. Obstetrical trauma: Trials that focused on perineal, high vaginal, or cervical laceration; uterine rupture; postpartum uterine inversion; obstetrical damage from instruments; obstetrical injury to pelvic organs; and/or pelvic hematoma
15. Thromboembolic disease of pregnancy: Trials that focused on deep vein thrombosis, amniotic fluid embolism, pyemic and septic embolism, and/or other obstetrical embolism (excluding cerebrovascular disease)
16. Vomiting in pregnancy: Trials that focused on excessive vomiting, hyperemesis gravidarum, late vomiting of pregnancy, and/or morning sickness
17. Other: Trials that focused on cerebrovascular disease (cerebral venous thrombosis, subarachnoid hemorrhage, and/or stroke), noninfectious liver disease in pregnancy (liver and biliary tract disorders, cholestasis of pregnancy, and/or acute fatty liver of pregnancy), and noninfectious renal disease in pregnancy (postpartum acute kidney failure, hepatorenal syndrome, kidney stones)
Trials could have multiple therapeutic foci. Enrollment included both actual enrollment (for completed trials) and anticipated enrollment (for ongoing trials with continued enrollment).

Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
### SUPPLEMENTAL TABLE 1
Characteristics of obstetrical and nonobstetrical clinical trials

| Trial feature                              | Nonobstetrical | Obstetrical | Chi² P value |
|--------------------------------------------|----------------|-------------|--------------|
| Total                                      | 219,235 (98.1) | 4276 (1.9)  |              |
| **Funding**                                |                |             |              |
| Industry                                  | 76,768 (35.0)  | 290 (6.8)   | <.0001       |
| United States government                   | 17,350 (7.9)   | 331 (7.7)   |              |
| Academic                                   | 125,117 (57.1) | 3655 (85.5) |              |
| **Primary purpose**                        |                |             |              |
| Treatment                                  | 140,234 (64.0) | 1681 (39.3) | <.0001       |
| Basic science                              | 12,154 (5.5)   | 106 (2.5)   |              |
| Prevention                                 | 22,394 (10.2)  | 1345 (31.5) |              |
| Other                                      | 37,961 (17.3)  | 1037 (24.3) |              |
| Missing                                    | 6492 (3.0)     | 107 (2.5)   |              |
| **Phase**                                  |                |             |              |
| Not Applicable                             | 99,542 (45.4)  | 2805 (65.6) | <.0001       |
| Phase 1                                    | 30,146 (13.8)  | 136 (3.2)   |              |
| Phase 1/2–2                                | 42,144 (19.2)  | 301 (7.0)   |              |
| Phase 2/3–3                                | 26,058 (11.9)  | 507 (11.9)  |              |
| Phase 4                                    | 21,345 (9.7)   | 527 (12.3)  |              |
| **Enrollment**                             |                |             |              |
| 0–9                                        | 16,056 (7.3)   | 204 (4.8)   | <.0001       |
| 10–49                                      | 78,930 (36.0)  | 641 (15.0)  |              |
| 50–99                                      | 45,792 (20.9)  | 789 (18.5)  |              |
| 100–499                                    | 61,257 (27.9)  | 1910 (44.7) |              |
| 500–999                                    | 8863 (4.0)     | 295 (6.9)   |              |
| >999                                       | 7628 (3.5)     | 422 (9.9)   |              |
| Missing                                    | 709 (0.3)      | 709 (0.3)   |              |
| **Blinding**                               |                |             |              |
| None                                       | 124,461 (56.8) | 2266 (53.0) | <.0001       |
| Double                                     | 50,675 (23.1)  | 922 (21.6)  |              |
| Single                                     | 43,125 (19.7)  | 1078 (25.2) |              |
| Missing                                    | 974 (0.4)      | 10 (0.2)    |              |
| **Randomization**                          |                |             |              |
| Nonrandomized                              | 74,065 (33.8)  | 822 (19.2)  | <.0001       |
| Randomized                                 | 142,302 (64.9) | 3420 (80.0) |              |
| Missing                                    | 2868 (1.3)     | 34 (0.8)    |              |
| **Oversight by a data safety monitoring committee** | | | |
| No                                         | 115,552 (52.7) | 2269 (53.1) | <.0001       |
| Yes                                        | 78,713 (35.9)  | 1635 (38.2) |              |
| Missing                                    | 24,970 (11.4)  | 372 (8.7)   |              |

*Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.*
SUPPLEMENTAL TABLE 1
Characteristics of obstetrical and nonobstetrical clinical trials (continued)

| Trial feature               | Nonobstetrical | Obstetrical | Chi^2 P value |
|-----------------------------|----------------|-------------|---------------|
| Location                    |                |             |               |
| High-income countries       | 158,210 (72.2) | 2557 (59.8) | <.0001        |
| Low- and middle-income countries only | 30,428 (13.9) | 1174 (27.5) |               |
| Missing                     | 30,597 (14.0) | 545 (12.7)  |               |

Values are number (percentage) unless indicated otherwise.

- Percentages may not sum up to 100 because of rounding.
- Funding categories were determined with data on the sponsor and collaborators. Industry funding includes trials with an industry sponsor or collaborating agency. United States government trials include remaining trials with a United States government sponsor or collaborating agency. Academic trials include all other trials.
- Other primary purposes include diagnostic, screening, supportive care, health services research, and other.
- On ClinicalTrials.gov, "Not Applicable" is used to describe trials without Food and Drug Administration–defined phases, including trials of devices or behavioral interventions.
- Enrollment included both actual enrollment (for completed trials) and anticipated enrollment (for ongoing trials with continued enrollment).

Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.

SUPPLEMENTAL TABLE 2
Yearly growth statistics for obstetrical trials

| Variable           | Annual growth rate | Annual growth rate Mann-Kendall P value | Relative annual growth rate | Relative annual growth rate Mann-Kendall P value |
|--------------------|--------------------|----------------------------------------|-----------------------------|---------------------------------|
| Obstetrical trials | 10.8%              | <.0001                                 |                             |                                 |
| Nonobstetrical Trials | 4.8%              | <.0001                                 |                             |                                 |
| Funding^3          |                    |                                        |                             |                                 |
| United States government | 2.8%         | .49                                    | −7.2%                       | .003                            |
| Industry           | 6.5%               | .02                                    | −3.8%                       | .05                             |
| Academic           | 12.4%              | <.0001                                 | 1.4%                        | .0007                           |
| Study location     |                    |                                        |                             |                                 |
| High-income countries | 7.9%               | .0005                                  | −1.4%                       | .007                            |

^3 The relative annual growth rate (the change in percent) compares the relative growth of subcategories within a single category. It measures the change in the proportion of trials within that subcategory as a function of all trials in the category.

^4 Funding categories were determined with data on the sponsor and collaborators. Industry funding includes trials with an industry sponsor or collaborating agency. United States government trials include remaining trials with a United States government sponsor or collaborating agency. Academic trials include all other trials.

Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
### SUPPLEMENTAL TABLE 3

Trial quantity and enrollment by therapeutic area of focus

| Therapeutic area of focus<sup>a</sup> | Trials | Enrollment<sup>b</sup> |
|--------------------------------------|--------|------------------------|
| Cesarean delivery                    | 686    | (16.0) 83,394 (2.4)    |
| Nutrition                            | 553    | (12.9) 147,584 (4.2)   |
| Other disease                        | 522    | (12.2) 798,361 (22.9)  |
| Labor anesthesia                     | 515    | (12.0) 67,789 (1.9)    |
| Infections                           | 438    | (10.2) 755,241 (21.6)  |
| Fetal indications                    | 422    | (9.9) 547,647 (15.7)   |
| Mental health                        | 354    | (8.3) 34,820 (1.0)     |
| Early delivery                       | 328    | (7.7) 188,101 (5.4)    |
| Diabetes mellitus                    | 307    | (7.2) 29,970 (0.9)     |
| Hemorrhage                           | 305    | (7.1) 154,760 (4.4)    |
| Labor Augmentation                   | 257    | (6.0) 40,946 (1.2)     |
| Hypertension                         | 254    | (5.9) 118,076 (3.4)    |
| Breastfeeding                        | 197    | (4.6) 56,389 (1.6)     |
| Pregnancy loss                       | 149    | (3.5) 446,114 (12.8)   |
| Trauma                               | 95     | (2.2) 15,585 (0.4)     |
| Thromboembolic                       | 24     | (0.6) 1881 (0.1)       |
| Vomiting                             | 21     | (0.5) 2658 (0.1)       |

<sup>a</sup>Trials could have multiple therapeutic areas of focus; <sup>b</sup>Enrollment included both actual enrollment (for completed trials) and anticipated enrollment (for ongoing trials with continued enrollment).

Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
**SUPPLEMENTAL TABLE 4**  
Obstetrical trial study status and enrollment on March 9, 2020

| Study status                  | Total trials | Total enrollment<sup>a</sup> |
|-------------------------------|--------------|-------------------------------|
| Completed                     |              |                               |
| Completed                     | 2032         | 2,870,525                     |
| Ongoing                       |              |                               |
| Active, not recruiting        | 192          | 218,518                       |
| Enrolling by invitation       | 31           | 33,787                        |
| Not yet recruiting            | 249          | 234,939                       |
| Recruiting                    | 899          | 693,661                       |
| Discontinued Early            |              |                               |
| Suspended                     | 10           | 1401                          |
| Terminated                    | 181          | 30,369                        |
| Withdrawn                     | 118          | 918                           |
| Unknown                       |              |                               |
| Unknown status                | 564          | 376,470                       |

<sup>a</sup> Enrollment included both actual enrollment (for completed trials) and anticipated enrollment (for ongoing trials with continued enrollment).

All definitions and terms as defined by the ClinicalTrials.gov glossary.<sup>1</sup>

Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
| Trail feature                  | Hazard ratio (95% confidence interval) | P value |
|-------------------------------|----------------------------------------|---------|
| **Funding**                   |                                        |         |
| Industry                      | Reference                              |         |
| Academic                      | 0.73 (0.45—1.18)                       | .20     |
| United States government      | 0.12 (0.04—0.35)                       | <.001   |
| **Primary purpose**           |                                        |         |
| Treatment                     | Reference                              |         |
| Basic science                 | 0.39 (0.12—1.30)                       | .12     |
| Prevention                    | 0.43 (0.29—0.62)                       | <.001   |
| Other                         | 0.76 (0.51—1.13)                       | .17     |
| **Phase**                     |                                        |         |
| Phase 2/3—3                   | Reference                              |         |
| Not Applicable                | 0.95 (0.61—1.50)                       | .84     |
| Phase 1                       | 1.79 (0.83—3.88)                       | .14     |
| Phase 1/2—2                   | 1.13 (0.56—2.27)                       | .73     |
| Phase 4                       | 1.04 (0.58—1.88)                       | .90     |
| **Enrollment**                |                                        |         |
| 100—499                       | Reference                              |         |
| 0—9                           | 32.45 (20.75—50.75)                    | <.001   |
| 10—49                         | 5.20 (3.39—7.99)                       | <.001   |
| 50—99                         | 1.68 (0.97—2.93)                       | .07     |
| 500—999                       | 0.72 (0.26—2.04)                       | .54     |
| >999                          | 0.81 (0.39—1.68)                       | .56     |
| **Year**                      |                                        |         |
| 2007—2013                     | Reference                              |         |
| 2014—2020                     | 1.17 (0.86—1.59)                       | .33     |
| **Blinding**                  |                                        |         |
| None                          | Reference                              |         |
| Double                        | 1.17 (0.83—1.66)                       | .37     |
| Single                        | 0.66 (0.43—1.00)                       | .053    |
| **Randomization**             |                                        |         |
| Nonrandomized                 | Reference                              |         |
| Randomized                    | 0.87 (0.59—1.28)                       | .48     |
| **Oversight by a data safety monitoring committee** |         |         |
| No                            | Reference                              |         |
| Yes                           | 0.83 (0.61—1.13)                       | .24     |
| **Location**                  |                                        |         |
| Low- and middle-income countries only | Reference                               |         |
| High-income countries         | 2.91 (1.68—5.04)                       | <.001   |
### SUPPLEMENTAL TABLE 5
Univariable analyses of association between trial between trail features and early discontinuation (continued)

| Trail feature          | Hazard ratio (95% confidence interval) | P-value |
|------------------------|---------------------------------------|---------|
| Number of facilities   |                                       |         |
| 1                      | Reference                             |         |
| >2                     | 0.92 (0.64—1.30)                      | .63     |
| Therapeutic focus<sup>3</sup> |                                     |         |
| All other therapeutic foci | Reference                         |         |
| Cesarean delivery      | 1.51 (0.95—2.38)                      | .08     |
| Nutrition              | 0.61 (0.37—0.99)                      | .046    |
| Anesthesia             | 2.16 (1.42—3.29)                      | <.001   |
| Infection              | 0.85 (0.52—1.41)                      | .53     |
| Fetal                  | 1.12 (0.72—1.75)                      | .61     |
| Mental health          | 0.77 (0.43—1.38)                      | .38     |
| Early delivery         | 1.47 (0.94—2.30)                      | .09     |
| Diabetes mellitus      | 1.00 (0.59—1.71)                      | .99     |

<sup>3</sup> Funding categories were determined with data on the sponsor and collaborators. Industry funding includes trials with an industry sponsor or collaborating agency United States government trials include remaining trials with a United States government sponsor or collaborating agency;<sup>3</sup> Other primary purposes include diagnostic, screening, supportive care, health services research, and other;<sup>3</sup> On ClinicalTrials.gov, “Not Applicable” is used to describe trials without Food and Drug Administration—defined phases, including trials of devices or behavioral interventions;<sup>3</sup> Enrollment included both actual enrollment (for completed trials) and anticipated enrollment (for ongoing trials with continued enrollment);<sup>3</sup> Trials could have >1 therapeutic focus. For analysis, each therapeutic focus was treated as a binary variable.

Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
### SUPPLEMENTAL TABLE 6

Univariable analyses of association between trial features and results reporting within 3 years of completion

| Trail feature                               | Odds ratio (95% confidence interval) | P-value |
|---------------------------------------------|---------------------------------------|---------|
| **Funding**                                 |                                       |         |
| Industry                                    | Reference                             |         |
| Academic                                    | 0.48 (0.27—0.82)                      | .008    |
| United States government                    | 0.93 (0.47—1.83)                      | .83     |
| **Primary purpose**                         |                                       |         |
| Treatment                                   | Reference                             |         |
| Basic science                               | 0.86 (0.33—2.26)                      | .76     |
| Prevention                                  | 0.71 (0.48—1.07)                      | .10     |
| Other                                       | 0.71 (0.44—1.14)                      | .15     |
| **Phase**                                   |                                       |         |
| Phase 2/3—3                                 | Reference                             |         |
| Not Applicable'                             | 0.68 (0.40—1.16)                      | .16     |
| Phase 1                                     | 0.81 (0.29—2.30)                      | .70     |
| Phase 1/2—2                                 | 1.42 (0.70—2.86)                      | .33     |
| Phase 4                                     | 1.23 (0.65—2.32)                      | .52     |
| **Enrollment**                              |                                       |         |
| 100—499                                     | Reference                             |         |
| 10—49                                       | 1.13 (0.71—1.78)                      | .61     |
| 50—99                                       | 0.87 (0.54—1.38)                      | .55     |
| 500—999                                     | 0.70 (0.31—1.59)                      | .40     |
| >999                                        | 0.44 (0.21—0.95)                      | .035    |
| **Year**                                    |                                       |         |
| 2007—2013                                   | Reference                             |         |
| 2014—2020                                   | 1.22 (0.85—1.73)                      | .28     |
| **Blinding**                                |                                       |         |
| None                                        | Reference                             |         |
| Double                                      | 1.30 (0.85—2.00)                      | .22     |
| Single                                      | 1.22 (0.80—1.86)                      | .36     |
| **Randomization**                           |                                       |         |
| Nonrandomized                               | Reference                             |         |
| Randomized                                  | 1.44 (0.87—2.38)                      | .16     |
| **Oversight by a data safety monitoring committee** |                       |         |
| No                                          | Reference                             |         |
| Yes                                         | 1.23 (0.87—1.74)                      | .25     |
| **Location**                                |                                       |         |
| Low- and middle-income countries only       | Reference                             |         |
| High-income countries                       | 2.04 (1.34—3.13)                      | <.001   |
| **Number of facilities**                    |                                       |         |
| 1                                           | Reference                             |         |
| >2                                          | 1.74 (1.18—2.56)                      | .005    |

*Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.*
### SUPPLEMENTAL TABLE 6
Univariable analyses of association between trial features and results reporting within 3 years of completion (continued)

| Trail feature          | Odds ratio (95% confidence interval) | P value |
|------------------------|--------------------------------------|---------|
| Therapeutic focus⁶     |                                      |         |
| All other therapeutic foci | Reference                           |         |
| Cesarean delivery      | 1.55 (1.01—2.37)                     | .043    |
| Nutrition              | 0.56 (0.31—0.99)                     | .046    |
| Anesthesia             | 1.52 (0.95—2.42)                     | .08     |
| Infection              | 1.12 (0.67—1.87)                     | .67     |
| Fetal                  | 1.16 (0.63—2.13)                     | .63     |
| Mental health          | 1.01 (0.53—1.95)                     | .97     |
| Early delivery         | 0.87 (0.39—1.94)                     | .74     |
| Diabetes mellitus      | 0.75 (0.35—1.58)                     | .45     |

⁶ Funding categories were determined with data on the sponsor and collaborators. Industry funding includes trials with an industry sponsor or collaborating agency United States government trials include remaining trials with a United States government sponsor or collaborating agency; Other primary purposes include diagnostic, screening, supportive care, health services research, and other; On ClinicalTrials.gov, “Not Applicable” is used to describe trials without Food and Drug Administration—defined phases, including trials of devices or behavioral interventions; Enrollment included both actual enrollment (for completed trials) and anticipated enrollment (for ongoing trials with continued enrollment); Trials could have >1 therapeutic focus. For analysis, each therapeutic focus was treated as a binary variable.

Steinberg et al. The obstetrical clinical trial landscape. AJOG MFM 2021.
### SUPPLEMENTAL TABLE 7
Association between trial features and results reporting within 3 years of completion

| Trial feature                                      | Odds ratio (95% confidence interval) | P value |
|----------------------------------------------------|--------------------------------------|---------|
| **All trials**                                     |                                      |         |
| Nonobstetrical                                     | Reference                            |         |
| Obstetrical                                        | 0.89 (0.72—1.10)                     | .19     |
| **Obstetrical trials only**                        |                                      |         |
| Funding                                             |                                      |         |
| Industry                                           | Reference                            |         |
| Academic                                           | 0.39 (0.22—0.68)                     | .0009   |
| United States government                           | 1.06 (0.53—2.09)                     | .87     |
| **Primary purpose**                                |                                      |         |
| Treatment                                          | Reference                            |         |
| Basic science                                      | 1.49 (0.62—3.56)                     | .37     |
| Prevention                                         | 0.98 (0.65—1.47)                     | .92     |
| Otherb                                             | 0.85 (0.51—1.43)                     | .54     |
| **Phase**                                          |                                      |         |
| Phase 2/3—3                                        | Reference                            |         |
| Not Applicablec                                     | 0.82 (0.47—1.43)                     | .49     |
| Phase 1                                            | 0.89 (0.34—2.39)                     | .82     |
| Phase 1/2—2                                        | 1.91 (0.99—3.70)                     | .05     |
| Phase 4                                            | 0.92 (0.47—1.79)                     | 80      |
| **Enrollment**                                     |                                      |         |
| 100—499                                            | Reference                            |         |
| 0—9                                                | 0.44 (0.05—3.56)                     | .44     |
| 10—49                                              | 1.08 (0.66—1.76)                     | .77     |
| 50—99                                              | 0.86 (0.55—1.35)                     | .53     |
| 500—999                                            | 0.62 (0.28—1.37)                     | .24     |
| >999                                                | 0.61 (0.31—1.21)                     | .16     |
| **Blinding**                                       |                                      |         |
| None                                               | Reference                            |         |
| Double                                             | 0.82 (0.52—1.31)                     | .41     |
| Single                                             | 0.90 (0.58—1.39)                     | .63     |
| **Randomization**                                  |                                      |         |
| Nonrandomized                                      | Reference                            |         |
| Randomized                                         | 1.36 (0.81—2.28)                     | .25     |
| Oversight by a data safety monitoring committee     |                                      |         |
| No                                                 | Reference                            |         |
| Yes                                                | 1.41 (0.98—2.04)                     | .07     |
| **Location**                                       |                                      |         |
| Low- and middle-income countries only               | Reference                            |         |
| High-income countries                              | 2.13 (1.35—3.36)                     | .001    |
### SUPPLEMENTAL TABLE 7

**Association between trial features and results reporting within 3 years of completion (continued)**

| Trial feature           | Odds ratio (95% confidence interval) | P-value |
|-------------------------|-------------------------------------|---------|
| **Number of facilities** |                                     |         |
| 1                       | Reference                           |         |
| ≥2                      | 1.22 (0.80—1.87)                    | .35     |
| **Therapeutic focus**   |                                     |         |
| All other therapeutic foci | Reference                          |         |
| Cesarean delivery       | 2.07 (1.29—3.34)                    | .003    |
| Nutrition               | 0.75 (0.44—1.29)                    | .30     |
| Anesthesia              | 1.07 (0.62—1.87)                    | .80     |
| Infection               | 1.25 (0.75—2.09)                    | .39     |
| Fetal                   | 0.75 (0.37—1.53)                    | .43     |
| Mental health           | 0.51 (0.23—1.12)                    | .09     |
| Early delivery          | 0.51 (0.23—1.12)                    | .88     |
| Diabetes mellitus       | 0.83 (0.39—1.77)                    | .63     |

---

* Funding categories were determined with data on the sponsor and collaborators. Industry funding includes trials with an industry sponsor or collaborating agency United States government trials include remaining trials with a United States government sponsor or collaborating agency; other primary purposes include diagnostic, screening, supportive care, health services research, and other; On ClinicalTrials.gov, “Not Applicable” is used to describe trials without Food and Drug Administration—defined phases, including trials of devices or behavioral interventions; Enrollment included both actual enrollment (for completed trials) and anticipated enrollment (for ongoing trials with continued enrollment); Trials could have >1 therapeutic focus. For analysis, each therapeutic focus was treated as a binary variable.

Steinberg et al. *The obstetrical clinical trial landscape. AJOG MFM 2021.*
### SUPPLEMENTAL TABLE 8

**Results reporting among trials completed by March 9, 2017**

| Funding Category            | Completed trials | Results reported by March 9, 2020 |
|----------------------------|------------------|-----------------------------------|
| **Total**                  | 1411             | 216 (15.3)                        |
| **Industry**               | 102              | 29 (28.4)                         |
| **Academic**               | 1171             | 149 (12.7)                        |
| **United States government**| 138              | 38 (27.5)                         |

Values are number (percentage) unless indicated otherwise.

- Only trials completed by March 8, 2017, were included in the analysis of results reporting to align with federal mandates for delayed submission of results information within 3 years of trial completion.
- Funding categories were determined with data on the sponsor and collaborators. Industry funding includes trials with an industry sponsor or collaborating agency. United States government trials include remaining trials with a United States government sponsor or collaborating agency. Academic trials include all other trials.

Steinberg et al. *The obstetrical clinical trial landscape. AJOG MFM 2021.*